Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

PURPOSE: Bevacizumab is an antibody that binds to vascular endothelial growth factor (VEGF) and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN) is a historic standard first-line treatment for RCC. A prospective, randomized phase III trial of bevacizumab plus IFN versus I...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rini, Brian I., Halabi, Susan, Rosenberg, Jonathan E., Stadler, Walter M., Vaena, Daniel A., Ou, San-San, Archer, Laura, Atkins, James N., Picus, Joel, Czaykowski, Piotr, Dutcher, Janice, Small, Eric J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2008
Assuntos:
Genitourinary Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2651074/
https://ncbi.nlm.nih.gov/pubmed/18936475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.16.9847
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados